Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 309

1.

A polymeric nanoparticle encapsulated small-molecule inhibitor of Hedgehog signaling (NanoHHI) bypasses secondary mutational resistance to Smoothened antagonists.

Chenna V, Hu C, Pramanik D, Aftab BT, Karikari C, Campbell NR, Hong SM, Zhao M, Rudek MA, Khan SR, Rudin CM, Maitra A.

Mol Cancer Ther. 2012 Jan;11(1):165-73. doi: 10.1158/1535-7163.MCT-11-0341. Epub 2011 Oct 25.

2.

Polymeric nanoparticle-encapsulated hedgehog pathway inhibitor HPI-1 (NanoHHI) inhibits systemic metastases in an orthotopic model of human hepatocellular carcinoma.

Xu Y, Chenna V, Hu C, Sun HX, Khan M, Bai H, Yang XR, Zhu QF, Sun YF, Maitra A, Fan J, Anders RA.

Clin Cancer Res. 2012 Mar 1;18(5):1291-302. doi: 10.1158/1078-0432.CCR-11-0950. Epub 2011 Aug 25.

3.

Adenovirus vector-mediated Gli1 siRNA induces growth inhibition and apoptosis in human pancreatic cancer with Smo-dependent or Smo-independent Hh pathway activation in vitro and in vivo.

Guo J, Gao J, Li Z, Gong Y, Man X, Jin J, Wu H.

Cancer Lett. 2013 Oct 10;339(2):185-94. doi: 10.1016/j.canlet.2013.06.010. Epub 2013 Jun 18.

PMID:
23791879
4.

Pituitary adenylyl cyclase activating polypeptide inhibits gli1 gene expression and proliferation in primary medulloblastoma derived tumorsphere cultures.

Cohen JR, Resnick DZ, Niewiadomski P, Dong H, Liau LM, Waschek JA.

BMC Cancer. 2010 Dec 9;10:676. doi: 10.1186/1471-2407-10-676.

5.

Targeting of the Hedgehog signal transduction pathway suppresses survival of malignant pleural mesothelioma cells in vitro.

You M, Varona-Santos J, Singh S, Robbins DJ, Savaraj N, Nguyen DM.

J Thorac Cardiovasc Surg. 2014 Jan;147(1):508-16. doi: 10.1016/j.jtcvs.2013.08.035. Epub 2013 Oct 4.

6.

Hedgehog-signaling is upregulated in non-producing human adrenal adenomas and antagonism of hedgehog-signaling inhibits proliferation of NCI-H295R cells and an immortalized primary human adrenal cell line.

Werminghaus P, Haase M, Hornsby PJ, Schinner S, Schott M, Malendowicz LK, Lammers BJ, Goretzki PE, Müller-Mattheis V, Markus Giessing, Willenberg HS.

J Steroid Biochem Mol Biol. 2014 Jan;139:7-15. doi: 10.1016/j.jsbmb.2013.09.007. Epub 2013 Sep 21.

PMID:
24063979
7.

Effective targeting of Hedgehog signaling in a medulloblastoma model with PF-5274857, a potent and selective Smoothened antagonist that penetrates the blood-brain barrier.

Rohner A, Spilker ME, Lam JL, Pascual B, Bartkowski D, Li QJ, Yang AH, Stevens G, Xu M, Wells PA, Planken S, Nair S, Sun S.

Mol Cancer Ther. 2012 Jan;11(1):57-65. doi: 10.1158/1535-7163.MCT-11-0691. Epub 2011 Nov 14.

8.

Response to inhibition of smoothened in diverse epithelial cancer cells that lack smoothened or patched 1 mutations.

Galimberti F, Busch AM, Chinyengetere F, Ma T, Sekula D, Memoli VA, Dragnev KH, Liu F, Johnson KC, Guo Y, Freemantle SJ, Andrew AS, Greninger P, Robbins DJ, Settleman J, Benes C, Dmitrovsky E.

Int J Oncol. 2012 Nov;41(5):1751-61. doi: 10.3892/ijo.2012.1599. Epub 2012 Aug 22.

9.

LKB1 inhibits breast cancer partially through repressing the Hedgehog signaling pathway.

Zhuang Z, Wang K, Cheng X, Qu X, Jiang B, Li Z, Luo J, Shao Z, Duan T.

PLoS One. 2013 Jul 4;8(7):e67431. doi: 10.1371/journal.pone.0067431. Print 2013.

10.

Combination of hedgehog signaling blockage and chemotherapy leads to tumor reduction in pancreatic adenocarcinomas.

Bahra M, Kamphues C, Boas-Knoop S, Lippert S, Esendik U, Schüller U, Hartmann W, Waha A, Neuhaus P, Heppner F, Pietsch T, Koch A.

Pancreas. 2012 Mar;41(2):222-9. doi: 10.1097/MPA.0b013e31822896dd.

PMID:
22076568
11.

DYRK1B as therapeutic target in Hedgehog/GLI-dependent cancer cells with Smoothened inhibitor resistance.

Gruber W, Hutzinger M, Elmer DP, Parigger T, Sternberg C, Cegielkowski L, Zaja M, Leban J, Michel S, Hamm S, Vitt D, Aberger F.

Oncotarget. 2016 Feb 9;7(6):7134-48. doi: 10.18632/oncotarget.6910.

12.

Synergism between Hedgehog-GLI and EGFR signaling in Hedgehog-responsive human medulloblastoma cells induces downregulation of canonical Hedgehog-target genes and stabilized expression of GLI1.

Götschel F, Berg D, Gruber W, Bender C, Eberl M, Friedel M, Sonntag J, Rüngeler E, Hache H, Wierling C, Nietfeld W, Lehrach H, Frischauf A, Schwartz-Albiez R, Aberger F, Korf U.

PLoS One. 2013 Jun 10;8(6):e65403. doi: 10.1371/journal.pone.0065403. Print 2013.

13.

All-trans-retinoic acid antagonizes the Hedgehog pathway by inducing patched.

Busch AM, Galimberti F, Nehls KE, Roengvoraphoj M, Sekula D, Li B, Guo Y, Direnzo J, Fiering SN, Spinella MJ, Robbins DJ, Memoli VA, Freemantle SJ, Dmitrovsky E.

Cancer Biol Ther. 2014 Apr;15(4):463-72. doi: 10.4161/cbt.27821. Epub 2014 Feb 4.

14.

Small molecule inhibition of GDC-0449 refractory smoothened mutants and downstream mechanisms of drug resistance.

Dijkgraaf GJ, Alicke B, Weinmann L, Januario T, West K, Modrusan Z, Burdick D, Goldsmith R, Robarge K, Sutherlin D, Scales SJ, Gould SE, Yauch RL, de Sauvage FJ.

Cancer Res. 2011 Jan 15;71(2):435-44. doi: 10.1158/0008-5472.CAN-10-2876. Epub 2010 Dec 1.

15.

Trisomy 12 and elevated GLI1 and PTCH1 transcript levels are biomarkers for Hedgehog-inhibitor responsiveness in CLL.

Decker S, Zirlik K, Djebatchie L, Hartmann D, Ihorst G, Schmitt-Graeff A, Herchenbach D, Jumaa H, Warmuth M, Veelken H, Dierks C.

Blood. 2012 Jan 26;119(4):997-1007. doi: 10.1182/blood-2011-06-359075. Epub 2011 Nov 30.

16.

Hedgehog inhibitor decreases chemosensitivity to 5-fluorouracil and gemcitabine under hypoxic conditions in pancreatic cancer.

Onishi H, Morifuji Y, Kai M, Suyama K, Iwasaki H, Katano M.

Cancer Sci. 2012 Jul;103(7):1272-9. doi: 10.1111/j.1349-7006.2012.02297.x. Epub 2012 May 17.

17.

Hedgehog signaling is a novel therapeutic target in tamoxifen-resistant breast cancer aberrantly activated by PI3K/AKT pathway.

Ramaswamy B, Lu Y, Teng KY, Nuovo G, Li X, Shapiro CL, Majumder S.

Cancer Res. 2012 Oct 1;72(19):5048-59. doi: 10.1158/0008-5472.CAN-12-1248. Epub 2012 Aug 8.

18.

Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma.

Yauch RL, Dijkgraaf GJ, Alicke B, Januario T, Ahn CP, Holcomb T, Pujara K, Stinson J, Callahan CA, Tang T, Bazan JF, Kan Z, Seshagiri S, Hann CL, Gould SE, Low JA, Rudin CM, de Sauvage FJ.

Science. 2009 Oct 23;326(5952):572-4. doi: 10.1126/science.1179386. Epub 2009 Sep 2.

19.

Hedgehog pathway inhibition in chondrosarcoma using the smoothened inhibitor IPI-926 directly inhibits sarcoma cell growth.

Campbell VT, Nadesan P, Ali SA, Wang CY, Whetstone H, Poon R, Wei Q, Keilty J, Proctor J, Wang LW, Apte SS, McGovern K, Alman BA, Wunder JS.

Mol Cancer Ther. 2014 May;13(5):1259-69. doi: 10.1158/1535-7163.MCT-13-0731. Epub 2014 Mar 14.

20.

MRT-92 inhibits Hedgehog signaling by blocking overlapping binding sites in the transmembrane domain of the Smoothened receptor.

Hoch L, Faure H, Roudaut H, Schoenfelder A, Mann A, Girard N, Bihannic L, Ayrault O, Petricci E, Taddei M, Rognan D, Ruat M.

FASEB J. 2015 May;29(5):1817-29. doi: 10.1096/fj.14-267849. Epub 2015 Jan 30.

Supplemental Content

Support Center